47 results on '"Dziadziuszko, R."'
Search Results
2. OA14.06 Divarasib Single-Agent Long-Term Follow-up and Atezolizumab Combination Treatment in Patients with KRAS G12C-Positive NSCLC
3. EP.11A.24 Clinical Prognostic Index for Immunochemiotherapy in Lung Cancer (CLIPI-LC)- A Prognostic Score for Advanced Non-Small-Cell Lung Cancer
4. OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC)
5. OA03.06 Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial
6. OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results
7. EP11.03-09 Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study
8. EP08.02-27 Trimodality Treatment of Superior Sulcus non-Small Cell Lung Cancer. An Institutional Series of 47 Consecutive Patients.
9. MA13.04 Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
10. 10 Osimertinib versus gefitinib followed by osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE trial
11. A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer.
12. Blue-dye intraoperative sentinel lymph node mapping in early non-small cell lung cancer.
13. Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer
14. Lung Function in Patients Operated for Chronic Pleural Empyema
15. P2.14-58 A Phase IIIb, Open-Label Study of Afatinib in Caucasian EGFR TKI-Naïve Patients with EGFRm+ NSCLC: An Interim Analysis
16. 95TiP DUART: A phase II study of durvalumab following radiotherapy in patients with unresectable, stage III NSCLC ineligible for chemotherapy
17. P87.01 Higher Dose Alectinib for Advanced RET+ NSCLC: Results from the RET+ Cohort of the Blood First Assay Screening Trial (BFAST)
18. OA11.06 IMpower133: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage Small-Cell Lung Cancer
19. MA12.06 STELLAR – Final Results of a Phase 2 Trial of TTFields with Chemotherapy for First-Line Treatment of Malignant Pleural Mesothelioma
20. MA11.05 Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact
21. OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
22. JCES 01.27 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial
23. MA 06.06 Assessment of RANK Prevalence and Clinical Significance in the NSCLC European Thoracic Oncology Platform Lungscape Cohort
24. OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses
25. IBS31.02 Novel Drug Access: Dream Versus Reality
26. MA14.02 Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases
27. P2.06-01 STELLAR Trial: Radiological Response Patterns of TTFields Plus Chemotherapy in First-Line Treatment of Malignant Pleural Mesothelioma
28. MA25.02 Searching for a Definition of Synchronous Oligometastatic (sOMD)-NSCLC: A Consensus from Thoracic Oncology Experts
29. P2.09-24 MERS67 is a Novel anti-NaPi2b Antibody and Demonstrates Differential Expression Patterns in Lung Cancer Histologic Subtypes
30. P2.01-81 Treatment of Superior Sulcus Tumor: A Twelve-Year Single-Center Experience
31. OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC
32. P1.04-011 Development of Novel Blood-Based Biomarker Assays in 1L Advanced/Metastatic NSCLC: Blood First Assay Screening Trial (BFAST)
33. P1.01-013 Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK+ NSCLC
34. MA 07.01 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial
35. Brain metastases in HER-2 positive metastatic breast cancer (MBC) patients.
36. 8/Porównanie standardowego (20 Gy/5x) i hypofrakcjonowanego (16 Gy/2x) paliatywnego napromieniania chorych na nieoperacyjnego, niedrobnokomórkowego raka płuca (NDRP): końcowe wyniki wieloośrodkowego badania randomizowanego
37. 78. Paliatywna radioterapia przerzutów do kości – techniki napromieniania w AM w Gdańsku w latach 1995–2002
38. 36. A prospective, randomized study to compare the value of two fractionation schemes of palliative radiotherapy for inoperable non-small cell lung cancer
39. 2100 ORAL Prediction of brain relapse (BR) in HER-2 positive metastatic breast cancer (MBC) patients (pts).
40. 96 INVITED Predictive biomarkers for EGFR inhibitors in lung cancer.
41. Relative dose intensity (RDI) relevance in adjuvant CMF chemotherapy of breast cancer.
42. 15/Miejscowo-regionalne wyleczenie znamiennie wydłuża czas do wystąpienia odległych przerzutów u chorych na miejscowo zaawansowanego raka piersi
43. Peripheral blood count nadirs during adjuvant CMF chemotherapy for breast cancer - lack of prognostic relevance
44. Factors determining late sequelae and risk of contralateral breast carcinoma in patients (pts) with locally advanced breast cancer (LABC) managed with radiotherapy (RT) as the primary locoregional treatment
45. 60. Factors detremining local control in patients (Pts) with locally advanced breast cancer (Labc) managed with radiotherapy (RT) as the primary locoregional treatment
46. 55. How often should we obtain complete blood counts (CBC's) from patients receiving radical radiation therapy?
47. 26 Ocena wyników pooperacyjnej radioterapii skojarzonej z 5-fluorouracylem u chorych na raka odbytnicy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.